- The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's ALDX ADX-2191 to treat retinitis pigmentosa (RP).
- ADX-2191 is a methotrexate for intravitreal injection.
- Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.
- Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.
- Related content: Benzinga's Full FDA Calendar.
Loading...
Loading...
ALDXAldeyra Therapeutics Inc
$2.08-3.70%
Edge Rankings
Momentum
9.67
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
